Trusted Resources: Evidence & Education
Scientific literature and patient education texts
A Second Course of Antithyroid Drug Therapy for Recurrent Graves’ Disease: An Experience in Endocrine Practice
source: European Journal of Endocrinology / European Federation of Endocrine Societies
year: 2015
authors: Liu X, Qiang W, Liu X, Liu L, Liu S, Gao A, Gao S, Shi B
summary/abstract:Objective:
There are scarce reports regarding the prognosis of a second course of antithyroid drug (ATD) therapy on recurrent Graves’ disease (GD). The aim of this study was to assess the long-term remission rate after a second ATD therapy and verify significant clinical predictors of a remission.
Design:
A prospective randomized clinical trial with long-term follow-up was conducted to evaluate the effects of a second course of ATD therapy.
Methods:
A total of 128 recurrent GD patients who had finished a first regular ATD therapy were enrolled in this study, and prescribed methimazole (MMI) treatment with titration regimen. The patients were randomly assigned to two groups when the drug doses were reduced to 2.5 mg daily (qd). Group 1 was discontinued with 2.5 mg qd after about 5 months. Group 2 was continuously reduced to 2.5 mg every other day (qod) after 5 months and then discontinued with 2.5 mg qod after about a further 5 months. The patients were followed for 48 months after drug withdrawal.
Results:
Of the total number of patients, 97 cases (75.78%) achieved permanent remission at the end of follow-up, with the recurrence of 31 cases (24.22%). The remission rate of group 2 (84.62%) was significantly higher than that of group 1 (66.67%) (P=0.024). Cox regression showed that the hazard ratio for recurrence decreased under a high or high normal TSH level at drug withdrawal.
Conclusion:
A second course of ATD therapy can bring about a satisfying long-term remission on recurrent GD. The drug dose of 2.5 mg qod and a high or high normal TSH level at drug withdrawal may increase the likelihood of permanent remission.
DOI: 10.1530/EJE-14-0704
read more full text
Related Content
-
Successful Re-Administration of Low-Dose of Methimazole (MMI) in Graves’ Disease Patients who Experienced Alle...Objective: When patients with Graves' d...
-
Treatment of Hyperthyroidism With Antithyroid Drugs Corrects Mild Neutropenia in Graves’ DiseaseContext: Neutropenia secondary to antit...
-
Quality of Life Is Worse at 6-10 Years after Radioactive Iodine Treatment of Graves’ Disease as Compared with Anti...Background: Graves’ disease is a comm...
-
Disease Presentation and Remission Rate in Graves’ Disease Treated With Antithyroid Drugs: Is Gender Really a ...Objective: Male gender is considered an...
-
Antithyroid Drugs (Beyond the Basics)Antithyroid drugs have several benefits ...
-
Predicting Risk of Recurrent Thyrotoxicosis Following Thionamide Withdrawal in Graves’ DiseaseBackground/Aim: Thionamides are a safe ...
-
Thyroglobulin Autoantibodies are Associated With Refractoriness to Antithyroid Drug Treatment for Graves’ Dise...Objective: The recurrence rate associat...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.